Announcements Trials

Browse Landscape

Phase

Status

Suspended 2 Unknown 1 Terminated 1 Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Hemangioma 3 Prostatic Neoplasms 2 Uterine Cervical Neoplasms 1 Melanoma 1 Hemangioma, Cavernous, Central Nervous System 1 Breast Neoplasms 1 Anxiety Disorders 1

Interventions

pembrolizumab 51 Ipilimumab 49 Cyclophosphamide 43 Nivolumab 40 aldesleukin 30 Interleukin-2 23 Vemurafenib 20 fludarabine 19 Temozolomide 18 fludarabine phosphate 15 dabrafenib 15 trametinib 12 Radiosurgery 10 Dacarbazine 10 CTLA-4 Antigen 10 spartalizumab 9 cobimetinib 9 binimetinib 9 Radiotherapy 9 poly ICLC 7 encorafenib 7 Paclitaxel 7 atezolizumab 6 Introns 6 Biopsy 6 montanide ISA 51 5 Carboplatin 5 epacadostat 4 MART-1 Antigen 4 Interferon alpha-2 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Melanoma × Propranolol × Clear all

NCT01705392 2017-02-24

Bevacizumab vs Dacarbazine in Metastatic Melanoma

Haukeland University Hospital

Phase 2 Terminated

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡